MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-10-16
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
80
Registration Number
NCT02183545
Locations
🇰🇷

1333.3.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

🇰🇷

1333.3.82002 Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of

Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults

Phase 3
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: Gingko biloba
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
120
Registration Number
NCT02181972

Safety and Tolerability of Pharmaton Capsules in Healthy Volunteers

Phase 2
Completed
Conditions
Healthy
Interventions
Drug: Pharmaton® without DMAE
Drug: Pharmaton® with DMAE
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
138
Registration Number
NCT02181959

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: low dose BI 201335 NA soft gelatine capsule (SGC)
Drug: high dose BI 201335 NA soft gelatine capsule (SGC)
Drug: high dose BI 201335 NA powder in bottle (PIB)
Drug: low dose BI 201335 NA powder in bottle (PIB)
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
34
Registration Number
NCT02182284

Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBF 1120 ES
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02182154

A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Ba253BINEB
First Posted Date
2014-07-08
Last Posted Date
2014-07-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
88
Registration Number
NCT02182661

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: BIBF 1120 ES
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
17
Registration Number
NCT02182141

Metamizol for the Treatment of Neoplastic Chronic Pain

First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6
Registration Number
NCT02181920

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
23
Registration Number
NCT02182336

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Phase 1
Completed
Conditions
Prostatic Neoplasms
Interventions
First Posted Date
2014-07-08
Last Posted Date
2025-01-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
21
Registration Number
NCT02182219
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy